AFT Pharmaceuticals (NZE:AFT, ASX:AFP) said it is on track to meet its fiscal 2026 operating earnings guidance of NZ$20 million to NZ$24 million, according to Thursday filings with the Australian and New Zealand bourses.
The company's Kiwi shares were down 1% in recent Thursday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.